NCT00882557

Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.

Conditions

• End-stage Renal Disease
• Renal Failure Chronic Requiring Hemodialysis

Interventions

Type	Name	Description
DRUG	daptomycin	intradialytic: 9 mg/kg during the last 30 minutes of dialysis
DRUG	daptomycin	6 mg/kg administered after a hemodialysis session

Timeline

• Start date: 2009-04-29
• Primary completion: 2009-07-17
• Completion: 2009-07-17
• First posted: 2009-04-16
• Last updated: 2018-02-06
• Results posted: 2011-10-25

Locations

2 sites across 1 country: United States